The Fifth Circuit Court of Appeals has ruled against the Food and Drug Administration (FDA) in a significant case involving e-cigarette manufacturers. The court's decision affects companies like NicQuid, L.L.C. and Wood Creek Vapory, which had their marketing applications denied by the FDA. This ruling is important as it could reshape how e-cigarette products are regulated and marketed in the United States.
The case, Vertigo Vapor, L.L.C. v. FDA, was filed on August 19, 2026, under docket number 24-60332. The petitioners, including NicQuid and Wood Creek Vapory, challenged the FDA's marketing denial orders (MDOs) for their products. These denials were based on the FDA's assessment that the products did not meet the appropriate public health standards.
The dispute arose after the FDA denied marketing applications for various flavored e-cigarettes, claiming they posed a significant risk to youth. The FDA argued that the products lacked sufficient evidence to show they would benefit adult smokers enough to outweigh the risks posed to young people. The case reached the Fifth Circuit after the petitioners sought judicial review of the FDA's decision.
The court ruled in favor of the petitioners, vacating the FDA's marketing denial orders and sending the case back to the agency for reconsideration. The judges on the panel included Circuit Judges Higginbotham, Smith, and Oldham. In their opinion, the court stated, "We direct the FDA, on remand, either to rethink the rule, to re-adopt it consistently with the APA’s information-forcing procedure that permits the many bound parties to have their say and contribute to rational and sound policy." This ruling emphasizes the need for the FDA to follow proper procedures when implementing regulations that affect a wide range of stakeholders.
The court's decision is significant because it challenges the FDA's approach to regulating e-cigarettes, particularly flavored products. The FDA had previously argued that flavored e-cigarettes attract young users, contributing to a public health crisis. However, the court found that the agency's application of the comparative efficacy standard was not properly established through the required notice-and-comment rulemaking process as mandated by the Administrative Procedure Act (APA).
The impact of this ruling could be far-reaching. It not only affects the specific companies involved but also sets a precedent that may influence how the FDA regulates other tobacco products in the future. Manufacturers of e-cigarettes and other flavored tobacco products may now have a clearer path to challenge FDA decisions. This ruling could also encourage more companies to apply for marketing authorizations for their products, knowing that they have legal recourse if their applications are denied.
Looking ahead, the FDA may choose to appeal this decision to the Supreme Court, although details on any potential appeal were not available in the court filing. The outcome of this case could have lasting implications for public health policy and the regulation of tobacco products in the United States.